A significant asymmetric distribution was observed in the malignant progression of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status, 1p/19q co-deletion status, IDH mutation status, glioma grading, and histological types of samples with elevated expression levels of GJC1 in both the CGGA and TCGA datasets (Figures 1A,B). This evidence concerns the gene GJC1 and central nervous system cancer.